CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Exclusion Criteria

• •4. Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year).
• •7. All of those patients must also meet the following criteria:
• •Expected survival \> 12 weeks. Creatinine \< 2.5 mg/dl ALT(alanine aminotransferase)/AST (aspartate aminotransferase)\< 3x normal Bilirubin \< 2.0 mg/dl Any relapse after prior SCT will make patient eligible regardless of other prior therapy.
• •Adequate venous access for apheresis, and no other contraindications for leukapheresis.
• •Ability to give informed consent.
• •1. Pregnant or nursing women may not participate.
• •2. Active HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time of screening.
• •3. Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
• •4. History of severe immediate hypersensitivity to any of the agents including cyclophosphamide, fludarabine, or aldesleukin.
• •5. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
• •6. The existence of unstable or active ulcers or gastrointestinal bleeding.
• •7. Patients need anticoagulant therapy (such as warfarin or heparin).
• •8. Patients need long-term antiplatelet therapy (aspirin at a dose \> 300mg/d; clopidogrel at a dose \> 75mg/d).